RecruitingOverweight and Obesity
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Eligible age
18–60 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in two adult populations: Pre Type 2 diabetes (Pre T2D) and Type 2 Diabetes (T2D) in adults who are affected by obesity.
Sponsor: Wave Life Sciences USA, Inc.
You may qualify if…
- ✓ Male and female participants aged 18 to 60 years
- ✓ BMI 28 to 35 kg/m2 which has been stable (±5%) for the previous 3 to 6 months (based on participant self-report or medical records). For participants considered for enrollment in a cohort expansion, BMI 28 to 40 kg/ m2 will be allowed.
- ✓ Healthy, in the opinion of the Investigator, as determined by prestudy medical history, physical examination, and clinical laboratory assessments
- ✓ Male and female participants aged 18 to 60 years
- ✓ BMI 35 to 50 kg/m2 (inclusive)
- ✓ Thyroid stimulating hormone is within normal range at Screening. May be on supplemental thyroid hormone as managed by their prescribing physician and stable within the last 60 days
- ✓ Have Pre T2D or T2D
You may not qualify if…
- ✕ History or presence of CV disease, including heart failure (New York Heart Association \[NYHA\] Class III or IV), myocardial infarction, angina, or clinically significant abnormal laboratory assessments
- ✕ History or presence of thyroid disorders
- ✕ Medical history or diagnosis of causes of liver disease
- ✕ Use of any siRNA agent in the prior 12 months
- ✕ Received an investigational agent within 90 days or 5 half-lives, whichever is longer, before the first dose of study drug or are in follow-up of another clinical study
- ✕ History of significant CV disease in the opinion of the Investigator.
- ✕ Use of prescription medications (ie, anti-obesity or psychiatric medications) within 14 days or 7 half-lives (whichever is longer) before the first dose of study drug, except for allowed antihypertensive medications and statins.
- ✕ Taking \>2 antihypertensive medications, or antihypertensive medication dose was changed in the 60 days prior to Screening.
Where it's recruiting
Maryland
Baltimore
Source: ClinicalTrials.gov · NCT06842186 · last updated 2026-06-02